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We are now well entering the exciting era of stem cells. Potential stem cell therapy holds great promise for the
treatment of many diseases such as stroke, traumatic brain injury, Alzheimer’s disease, Parkinson’s disease, amyotrophic
lateral-sclerosis, myocardial infarction, muscular dystrophy, diabetes, and etc.. It is generally believed that transplantation
of specific stem cells into the injured tissue to replace the lost cells is an effective way to repair the tissue. In fact, organ
transplantation has been successfully practiced in clinics for liver or kidney failure. However, the severe shortage of
donor organs has been a major obstacle for the expansion of organ transplantation programs. Toward that direction,
generation of transplantable organs using stem cells is a desirable approach for organ replacement and would be of
great interest for both basic and clinical scientists. Here we review recent progress in the field of organ generation
using various methods including single adult tissue stem cells, a blastocyst complementation system, tissue
decellularization/recellularization and a combination of stem cells and tissue engineering.
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Stem cells are undifferentiated cells found in the body
which have the ability to continuously divide, self-renew
themselves and differentiate into various kinds of cells.
With the capability of self-renewal, pluripotency and dif-
ferentiation, stem cells have been believed to be useful
for treatment of a wide variety of diseases in the future,
including stroke, traumatic brain injury, Alzheimer’s di-
sease, Parkinson’s disease, spinal cord injury, baldness,
blindness, deafness, wound healing, amyotrophic lateral-
sclerosis, myocardial infarction, muscular dystrophy,
osteoarthritis rheumatoid arthritis, Crohn’s disease, and
diabetes. Amongst the applications, a number of adult
stem cell therapies have already been practiced clinically.
As an example, hematopoietic stem cell transplantation
has been successfully applied to treat leukemia.
In addition to cell replacement therapy using stem
cells, organ transplantation has been successfully prac-
ticed in clinics for organ failure of the liver or kidney.
However, the severe shortage of donor organs has be-
come the main obstacle to expand the organ transplant* Correspondence: yangru@yahoo.com; gao.weiqiang@sjtu.edu.cn
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reproduction in any medium, provided the orprogram. Generation of biological or semi-biological
organs could be an alternative approach to solve the
problem of the donor organ shortage. Notably, resear-
chers have been hunting for ways to establish a whole
organ using stem cells.
In recent years encouraging approaches for functional
organ generation have emerged. The present manuscript
provides an overview of organ generation using a single
adult tissue stem cell, a blastocyst complementation
system coupled with a specific stem cell niche, a method
of decellularization and recellularization of bio-scaffold,
and a combinatorial approach of tissue engineering and
stem cells.Generation of a functional organ from a single adult
tissue stem cell
To demonstrate whether there are true stem cells in a
given tissue, one needs to show that a single stem cell
purified from the tissue has the capability of generating
the entire organ. Up to present, it has been elegantly
shown by independent groups that the mammary gland
and the prostate can be generated in vivo from a single
adult tissue stem cell [1-3].
Two laboratories have reported independently that
single stem cells isolated from adult mouse mammary
glands are able to produce secretory mammary glandsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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It is long believed that there are stem cells in the mam-
mary glands because this organ has the capability of
undergoing an extensive growth at puberty and a second
phase of expansion and retraction during pregnancy
under the regulation of estrogen [4]. However, due to
the lack of defined markers, there has been no reliable
method to isolate mammary stem cells. This hypothesis
was not proven until the work by the two groups. Based
on some previous work by Clark and colleague [5], Shack-
leton et al. isolated putative mouse mammary stem cells
using specific cell-surface markers (Lin-, CD29hi, CD24+)
by FACS. They demonstrated these Lin-CD29hiCD24+
mammary cells have in vitro sphere formation capability
and the ability to repopulate all mammary epithelial cells
after transplantation into the fat-pad. Importantly, the
investigators employed a lineage-tracer in the stem cells so
to follow their ultimate phenotypes in vivo. They showed
elegantly that a single cell within the Lin-CD29hiCD24+
population of the mouse mammary gland, marked with a
LacZ report transgene, can reconstitute a completely func-
tional mammary gland in vivo. Notably, the transplanted
cell contributes to both the luminal and myoepithelial
lineages and generates milk-producing lobuloalveolar units
during pregnancy. This is the first report to demonstrate
that a single adult tissue stem cell has multi-lineage diffe-
rentiation capacity to produce a functional organ in an
in vivo setting.
Similarly, using a colony-formation in vivo assay and
an in vivo renal capsule transplantation approach, Gao
and his colleagues have also reported that a single stem
cell isolated from the adult mouse prostate epithelium
has the capacity to generate a functional prostate [3].
Actually, prostate stem cells were postulated to exist
because of its regenerative feature following androgen
deprivation and replacement more than twenty years
ago [6]. Because cell death mainly occurs in the luminal
cell compartment after castration and cell proliferation
mainly happens in the basal compartment following an-
drogen replacement, stem cells are generally believed to
reside in basal cell compartment and are able to repopu-
late the entire prostate epithelial cells.
First, this group identified a new marker for prostate
stem cells, CD117, based on the following 6 features: 1) It
is enriched in proximal region of the prostate; 2) It is
mainly expressed in basal cell population; 3) It is upregu-
lated after castration and returned to normal levels follo-
wing androgen replacement; 4) Only CD117+ cells, but
not the CD117- cells, can form colony structures with
lumen in vitro; 5) It can generate prostate epithelial glan-
dular structures in vivo; 6) CD117+ cells from 2nd and 3rd
generation grafts also have the self-renewal capability.
To demonstrate whether a single stem cell has the abi-
lity to generate a prostate structure, the investigators firstfurther enriched the stem cell population by sorting the
cells expressing multiple stem cell markers, Sca-1+CD133
+CD44+CD117+, into individual wells of a 96-well plate,
verified them under a microscope, and transplanted them
in a combination with rat embryonic urogenital sinus
mesenchymal cells (rUGM) under the renal capsule of
athymic nu/nu mouse hosts. Three months later, they
removed the kidneys and analyzed the fate of the grafted
cells. Of the 97 single-cell transplants, there were about 1/
7 Sca-1+CD133+CD44+CD117+ grafts that demonstrate a
branching pattern with epithelial tubules composed of
prostatic basal, luminal and neuroendocrine lineages by
the histological and immunocytochemical examination.
The generation of mammary gland and prostate acini
from single stem cell implants in mice is a major break-
through. These findings raise the possibility that people
who have lost their mammary glands or prostates due to
cancer could grow new ones. On the other hand, it is
believed that in some tissues, there are cancer stem cells
that are tumor-initiating cells. Cancer stem cells might
be derived from normal stem cells in which specific
tumor suppressor genes are mutated or lost [7]. There-
fore, although the prostate glands were grown in mice
but the research may aid the identification of markers
for cancer stem cells, which may help diagnosis and
more efficient treatment of prostate cancer in humans.
These studies on reconstruction of mammary and pros-
tate glands using single adult stem cells have important
ramifications not only for tissue repair/regeneration, but
also for identification of mammary and prostate cancer
stem cells. In other words, we envision that the potential
use of single stem cells in clinic will ultimately change
the treatment paradigm for human disorders more than
mammary gland injury and prostatic disease.
Generation of organs using a blastocyst complementation
system
In addition to single stem cells prepared from specific
adult tissue, embryonic stem cells (ESCs) have been shown
to be able to produce specific organs by using a strategy of
injection of ESCs from one species into the blastocyst of
another species. The development of a specific organ can
be precluded by genetic manipulation in the recipient spe-
cies but still providing a niche for organ development. The
pluripotent stem cell-derived cells from the donor species
would then developmentally compensate for the defect
and produce the missing organ.
The blastocyst complementation system was first
reported by Chen et al. by implanting normal mouse
embryonic stem cells (mESCs) into the blastocysts
derived from Rag2−/− mice to generate T and B lympho-
cyte lineages [8]. In recent years, this system was applied
to generate pluripotent stem cell (PSC)–derived donor
organs in vivo due to the fact that complex cellular
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for organogenesis are difficult to recapitulate in vitro.
For this purpose, PSCs were injected into blastocysts
obtained from mutant mice in which the development
of a certain organ was precluded by genetic manipula-
tion just to supply as a niche for organ development.
The PSC-derived cells would form the missing organ as
a result of developmental compensation for the defect.
Kobayashi and colleagues had showed proof-of-principle
findings of pancreas generation by injection of PSCs
into the blastocysts of pancreas-deficient Pdx1−/− mouse
(pancreatogenesis-disabled) [9]. More specifically, they
injected induced pluripotent stem cells (iPS) taken from
rats into the blastocysts of mice that were unable to grow
their own pancreas and were unable to produce insulin.
The rat stem cells grew in the special mouse environment
in the absent of mouse pancreas. When the mice matured
to adulthood, they developed a rat pancreas from the
injected rat stem cells. The origin and function of pancre-
atic cells were analyzed in the PSC-derived rat pancreas in
adult mice. Glucose load was tested and the mice showed
no signs of diabetes. These findings clearly indicate that
functional rat pancreas are successfully generated in Pdx1−/−
mice using the inter-species blastocyst complementation.
The same technique has been also used to generate
kidney using Sall1−/− mouse blastocysts [10]. Rat ESC or
PSC are injected into Sall1−/− mouse blastocysts and the
entire rat kidneys are formed by the injected mouse
ESC- or PSC-derived cells. These ESC/PSC-derived kid-
neys connect with ureters and function well. The blad-
ders are full of urine.
Generation of pancreas and kidney via blastocyst com-
plementation is an innovative approach. It demonstrates
that this technique can be used to generate complex
organ using donor PSCs. With an empty developmental
niche, a solid organ will be produced developmentally
from PSCs-derived cellular progeny in the vacant space.
The current organ shortage means that patients must
endure a long time on waiting lists for transplantation.
This blastocyst complementation system may therefore
provide a novel approach for organ supply. The ultimate
goal of blastocyst complementation system is to generate
specific human organs from various pluripotent stem
cells. However, such inter-species technology using
human stem cells involves ethical issues which has to
meet the scientific and ethical guidelines proposed by
the International Society for Stem Cell Research (ISSCR)
and requires approval from related ethical committees.
Engineering a whole organ via decellularization of matrix
bioscaffolds and recellularization with stem cells
Organ formation requires not only stem cells but also
the surrounding stem cell niche or microenvironment
and extracellular matrix participation. In fact, three-dimensional tissue scaffold has been demonstrated to be
very critical for organ regeneration.
Decellularization and recellularization of matrix bios-
caffolds have been shown to be a promising approach
for whole-organ tissue engineering in recent years [11].
Donor organs such as the heart [12], liver [13], lung
[14], kidney [15] and bladder [16] can be decellularized
to an acellular biologic scaffold material and then be
recellularized with functional parenchymal cells and/or
selected progenitor cell populations. Encouraging results
have emerged in animal model studies.
Taylor and colleagues have generated a bioartificial
heart which has a heart structure with appropriate cell
composition and cardiac pump function using this at-
tractive technique in 2008 [12]. They perfused heart with
1% SDS, a strong ionic detergent, to produce acellular
scaffolds, preserved extracellular matrix and original
microvascular network, and then repopulated these
heart-like constructs with neonatal cardiomyocytes and
aortic endothelial cells. When proper physiological stim-
uli were given, the recellularized organ in the culture
was able to further mature and display beating beha-
viors. Rhythmic contractions were observed by day 4,
pump function generated by day 8 and cardiac architec-
ture was formed, as confirmed by histological analysis.
The bioartificial heart pumped with an amazing func-
tion, which was equivalent to about 2% heart power of
an adult or 25% heart function of a 16-week fetus.
Uygun and colleagues modified Taylor’s perfusion decel-
lularization technique to achieve transplantable liver grafts
in 2010 [13]. The ischemic livers were perfused through
the portal vein with SDS. The intact lobular structure and
vascular network were retained in the decellularized liver
bioscaffold. The reseeded adult hepatocytes and nonpar-
enchymal cells were able to repopulate to create a recellu-
larized whole liver graft. The graft was transplanted as
auxiliary heterotopic graft with portal vein arterializations
and animal was shown to be viable for 8 hours after trans-
plantation. The hepatocytes in the recellularized liver graft
were metabolically active with functions of urea and
albumin secretion. Similarly, Niklason and colleagues
regenerated lung grafts using the decellularization and
recellularization strategy in 2010 [14]. They removed cel-
lular components from lung matrix, preserved hierarchical
branching structures of the airways and vasculature bed in
the extracellular scaffold, and reseeded pulmonary and
vascular endothelial cells in the acellular lung matrix.
The engineered lungs presented pneumonocyte viability
and function after implantation, as evidenced by oxygen
exchange.
These exciting studies on complex organs, such as the
heart, liver and lung as described above, provide insights
into the power of the methodology. The technology has
multiple advantages. First, a bioartificial organ could
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pression after organ transplantation. Second, the pre-
served extracellular matrix and three-dimensional scaffold
provide important signals for engraftment of repopulated
cells, survival of engrafted cells, and function of newborn
organ. Third, the vascular bed in the decellularized bios-
caffold allows oxygen and nutrient rapid to be delivered
after recellularization and reconnection to the circulation.
The most important concern in the technology is the
cell type and the source of cells used for filling the decellu-
larized organ matrix. Different types of cells are needed to
reconstruct the parenchyma, vasculature, and support
structures underneath. An ideal strategy is that a stem or
progenitor cell can self-renew and differentiate into he-
terogeneous types of cells as needed to form a functional
organ. Currently, cell sources are broadly categorized.
Stem or progenitor cells used for recellularization include
embryonic stem cells (ESCs), fetal cells, adult-derived stem
or progenitor cells and adult tissue-derived inducible
pluripotent stem cells (iPSCs). Non-stem or progenitor
cells used for repopulation are usually parenchymal cells
(e.g. cardiomyocytes, hepatocytes, pneumonocytes), vascu-
lar cells (e.g. endothelial cells) and supportive cells (e.g.
fibroblasts). Whether autologous or allogeneic cells are
utilized will depend on cell numbers required and if the
need is immediate.
In short, decellularization and recellularization tech-
nique is a potential breakthrough in whole-organ tissue
engineering. With further development, organs (e.g. heart,
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Generation of organs by a combination of tissue-
engineering and seeded stem cells
Tissue-engineering techniques have been used to com-
bine specific stem cells with biocompatible and bio-
degradable polymer scaffolds to produce a cell polymer
implant. The field of tissue engineering has been deve-
loped to solve the problem of donor-tissue scarcity
either as whole organs or as reconstructive grafts, such
as cartilage frameworks for total ear reconstruction
[17,18]. Cao and colleagues were the first to apply poly-
glycolic acid-polylactic acid to form a polymer template
in the shape of a human auricle and seeded chondro-
cytes into the construct. New tissue-engineered cartilage
grew for 12 weeks after implantation under the dorsal
skin of mice. The polyglycolic acid-polylactic acid con-
struct degraded gradually following transplantation, but
the cartilage was formed and confirmed by morpho-
logical and histological analysis [17]. The technique is
particularly useful for plastic and reconstructive surgery.
But this system, for quite a long time, seems mainly
focused on the exterior instead of the interior of the
function of the organ because of the key challenge to
integrate fully functioning vascular architectures into the
engineered construct. Therefore, the generation of func-
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well-vascularized organs including the liver and seems to
solve the major obstacles in regenerating thick, complex
tissues. They co-cultured human umbilical vein endothe-
lial cells and mesenchymal stem cells in a matrix made
of collagen and fibronectin. The human umbilical vein
endothelial cells were labeled with GFP and the human
mesenchymal stem cells were with kusabira orange.
Vessel-like constructs were formed and detected under a
fluorescence microscope in vitro seven days after cultiva-
tion. More importantly, when the vascular network con-
structs were implanted into an immunodeficient mouse,
they were able to infuse the structures with rhodamine
dextran to confirm that the structures can act as func-
tional vessels. Study in this direction will facilitate future
reconstitution of vascularized human organs [19].
Conclusions
In summary, as described above, there are four major
ways of generation of functional organs using stem cells
(Figure 1). Each of them has its own uniqueness. Specifi-
cally, using adult stem cells such as adult tissue epithelial
stem cells, there will be a very low risk of tumorigenesis,
more selective differentiation capability and better integra-
tion into the related tissue mass and acquisition of rele-
vant organ functions. However, the number of the adult
tissue stem cells that can be isolated is a limiting factor.
Although using blastocyst complementation system is an
attractive approach, particularly using a human-porcine
inter-species strategy, injection of human stem cells into
an organ-deficient porcine embryo is currently forbidden
for ethical reasons. In fact, blastocyst complementation
across species of large livestock animals such as porcine
and canine has not been experimentally proven, more
studies are needed in this direction. While the decellulari-
zation and recellularization research on various types of
organs including the heart, liver, lung, kidney, bladder, etc.
has yielded exciting results, but it is not practical to get
the donor organs for such approach from the human
beings. In addition, the acquisition of the organ functions
from these studies is still limited. Tissue engineering using
various biomaterial scaffolds holds hopes for particular
medical needs such as plastic and reconstructive surgery,
however the scaffolds using particular biomaterials are still
primitive and require further development and research.
Finally, the stem cell types that can be considered to be
used for generation of functional organs may include ESC,
iPSC and adult tissue cells. Each of these cell types has dif-
ferent advantages and disadvantages, in terms of prolifera-
tion, differentiation and tumorigenicity risk, which have
been well-discussed in the literature.
Although organogenesis is a complex process, the organ
generation systems described above using stem cells or a
combination of stem cells and tissue engineering may beapplied, or at least raise the hope, to treat organ failure in
humans in the near future. Besides adult tissue stem cells
and embryonic stem cells, recent burgeoning and promis-
ing development of technology of induced pluripotent
stem cells opens a new avenue for potential cell replace-
ment and organ generation. Relevant to generation of
functional organs, it is worth-mentioning that functional
hepatocyte-like cells can be generated from induced pluri-
potent stem cells and the liver can be partially reconsti-
tuted in Fah−/− mice [20].
Taken together, with the above initial steps and further
improvement, stem cell therapy may one day not only
repair tissue damage but also generate new tissues for
tissue/organ transplantation. Even though it is still at an
infancy stage, these studies may hold promise for gener-
ation of specific functional organs for organ transplant-
ation, to help solve the clinical problem of donor
shortage.
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